Ricardo Zaldivar
Medical · Pinellas Park, FLNPI 1548410988
Payments from drug & device makers
Across 150 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$735
- Collegium Pharmaceutical, Inc.$645
- AbbVie$257
- Abbott$175
- Novo Nordisk$165
- Lilly USA, LLC$96
- plus $480 from 16 others
What the payments were for
- Food & beverage$2,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 35 | $735 |
| Collegium Pharmaceutical, Inc. | 57 | $645 |
| AbbVie | 13 | $257 |
| Abbott | 3 | $175 |
| Novo Nordisk | 10 | $165 |
| Lilly USA, LLC | 4 | $96 |
| Exact Sciences | 3 | $89 |
| SPR Therapeutics, Inc | 4 | $50 |
| Daiichi Sankyo Inc. | 2 | $40 |
| IBSA Pharma Inc. | 2 | $38 |
| Merck | 3 | $38 |
| Amgen | 2 | $30 |
| Pfizer | 2 | $29 |
| Amarin Pharma, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| AstraZeneca | 2 | $24 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Vistapharm, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,553 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $16,603 |
| JanuviaSitagliptin Phosphate | 15 | $10,111 |
| MyrbetriqMirabegron | 12 | $4,970 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $515 |
| Metoprolol Succinate | 41 | $394 |
| Diclofenac Sodium | 16 | $384 |
| Metformin Hcl | 54 | $303 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $196 |
| FenofibrateFenofibrate Nanocrystallized | 18 | $193 |
| Rosuvastatin Calcium | 33 | $177 |
| Tamsulosin Hcl | 17 | $144 |
| Atorvastatin Calcium | 46 | $131 |
| Amlodipine Besylate | 32 | $129 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $125 |
| Glipizide | 14 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $165 | $16,60311 claims |
| MerckJanuvia | $38 | $10,11115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.
Other medical in Pinellas Park
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.